** Shares of some U.S. drugmakers fall premarket after U.S. President Donald Trump reiterated plans for a "major" tariff on all pharmaceutical imports as his "reciprocal" tariffs took effect
** Trump had also threatened the duties on Friday, after his first set of "reciprocal" tariffs announced last week exempted pharma products
** Shares of Gilead Sciences GILD.O down 2.6%, Eli Lilly LLY.N down 1.5%, Biogen BIIB.O down 1.1% and Pfizer PFE.N down 2.8%
** Amgen AMGN.O shares fall 2.3%, Merck MRK.N down 2%, AbbVie ABBV.N down 2.5%
** The U.S. president has said that the tariffs will incentivize drug companies to move their operations to the U.S.
** Brokerage BMO Capital Markets says the tariffs on pharmaceuticals will "likely do little to shift manufacturing back to the US" as the country already has robust biomanufacturing and fill-and-finish onshore
** Up to last close, LLY down 5.9%, MRK down 20.6%, BIIB down 25.4%, AMGN up 7.5% and GILD up 11.7% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。